Yahoo Web Search

Search results

  1. At Lonza, we enable a healthier world by supporting our healthcare customers on the path to commercialization. Working across five continents, our global community of around 18,000 colleagues helps pharmaceutical, biotech and nutrition companies to bring their treatments to market.

  2. en.wikipedia.org › wiki › Lonza_GroupLonza Group - Wikipedia

    Lonza Group AG is a Swiss multinational manufacturing company for the pharmaceutical, biotechnology and nutrition sectors, headquartered in Basel, with major facilities in Europe, North America and South Asia. Lonza was established under that name in the late 19th-century in Switzerland.

  3. www.lonza.com › about-usAbout Us | Lonza

    Lonza is one of the world’s largest healthcare manufacturing organizations, helping pharmaceutical, biotech and nutrition companies to bring their treatments to market. United by our vision to bring any therapy to life, we support our customers with a combination of technological insight, world-class manufacturing, scientific expertise ...

  4. www.lonza.com › careersCareers | Lonza

    1 day ago · Find your job opportunity at Lonza and become part of our global teams. Submit your application now and get one step closer to making a meaningful... Learn more

  5. www.linkedin.com › company › lonzaLonza | LinkedIn

    Lonza | 325,506 followers on LinkedIn. A Meaningful Difference for 125 Years | At Lonza, we enable A Healthier World by supporting our healthcare customers on the path to commercialization.

  6. We provide life science researchers with the tools they need to develop and test therapeutics, from basic research to final product release. Lonzas Bioscience products and services range from cell culture and discovery technologies for research, to quality control tests and software for biomanufacturing.

  7. 1 day ago · Furthermore, Lonza welcomed its new Chairman of the Board of Directors, Jean-Marc Huët, and announced the appointment of its new CEO Wolfgang Wienand, who joined Lonza on 1 July. Looking to H2 2024, group sales are expected to be higher than H1, reflecting the timing of batch releases and the ramp-up of new facilities in Biologics and Small ...